AOD-9604 (10 mg Vial) Dosage Protocol

Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).

• Peptide Vials (AOD-9604, 10 mg each):
  • 8 weeks: approximately 3 vials required
  • 12 weeks: approximately 4 vials required
• Insulin Syringes (U‑100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
• Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • 8 weeks (3 vials): 9 mL - 1 bottle required (10 mL each)
  • 12 weeks (4 vials): 12 mL - 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs - 2 boxes required (100 swabs each)

AOD-9604 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.333 mg/mL (3333 mcg/mL) concentration.
• Daily range: 300–500 mcg once daily (gradual titration).
• Easy measuring: At 3.333 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
• Storage (general laboratory handling): Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. See the formulation limits in Storage Instructions below.^[17]

AOD-9604 is a modified fragment based on the C-terminal region of human growth hormone. Animal research investigated its effects on lipid metabolism.^[1][4] Human safety findings summarized oral and intravenous studies; they do not establish a placebo-like safety profile for subcutaneous administration of this 10 mg vial preparation.^[2] FDA’s 2024 review found no human subcutaneous clinical data and insufficient evidence of effectiveness for obesity.^[3]

Concise summary of the once‑daily regimen.

• Goal: Support reduction of fat mass and enhance fat oxidation over time^[1][4].
• Schedule: Daily subcutaneous injections for 8–12 weeks.
• Dose Range: 300–500 mcg daily with gradual titration.
• Reconstitution: 3.0 mL per 10 mg vial (~3.333 mg/mL) for accurate unit measurements.
• Storage (general laboratory handling): Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw. Product-specific directions take precedence.^[17]

Suggested daily titration approach.

• Start: 300 mcg daily for Weeks 1–4; increase to 500 mcg for Weeks 5–12 as tolerated.
• Target: 500 mcg daily by Week 5 and maintain through cycle completion.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks.
• Timing: Morning administration (fasted) is common; rotate injection sites.

General peptide guides provide a laboratory handling reference, not a validated shelf life for this AOD-9604 10 mg preparation. The exact product’s documented instructions take precedence.

• Dry powder: Keep lyophilized peptide tightly capped and dry. General laboratory guidance uses a freezer at −4 °F (−20 °C) for frozen storage and advises avoiding repeated freeze–thaw cycles.^[17]
• After mixing: Sigma’s general peptide guide describes short-term refrigeration around 39 °F (4 °C), within the refrigerated range shown above. This is not a guarantee of stability for every peptide solution. Keep the vial capped and avoid repeated freeze–thaw cycles.^[17]
• Light and handling: Protect laboratory peptide preparations from direct light and minimize unnecessary handling.^[18]

No validated use-by period is assigned here. Stability testing needs to match the actual formulation and reconstituted concentration. Refrigeration and bacteriostatic water do not establish this vial’s potency, sterility or a 28-day usable life.^[19]

AOD-9604 10 mg dosage arithmetic depends on both vial mass and final volume. With 10 mg in 3 mL, the calculated concentration is about 3.333 mg/mL. At that concentration, each U-100 unit contains about 33.33 mcg.

AOD 9604 dosage calculations cannot establish a treatment protocol. The human safety literature summarized oral and intravenous studies. Those findings do not validate subcutaneous administration of a commercially supplied vial.^[2][3]

AOD-9604 is a modified fragment based on the C-terminal region of human growth hormone. Researchers investigated its metabolic effects, but the fragment’s proposed actions should not be treated as the established actions of full-length growth hormone.^[1]

In obese mice and mice lacking the beta-3 adrenergic receptor, investigators examined lipid metabolism and the receptor’s role in the response. That experiment provides animal-model evidence, not proof that an AOD-9604 injection produces weight loss in people.^[4]

The 2013 human safety report summarized six randomized trials involving oral or intravenous AOD-9604. It reported no significant increase in IGF-I and generally similar adverse-event findings between study groups under those tested conditions. It did not establish a safety profile for this subcutaneous preparation.^[2]

FDA’s 2024 compounding review found no human subcutaneous clinical data and insufficient evidence of effectiveness for obesity. A selected result from an earlier trial cannot resolve those broader limitations.^[3]

FDA also identifies limited safety information, possible immunogenicity and impurity-related concerns, and serious adverse events that may be associated with AOD-9604. The agency notes that causality is unclear. That is a reason for caution, not proof that every reported event was caused by the compound.^[15]

Check the route before interpreting a result. Oral exposure, intravenous exposure, and a subcutaneous vial protocol are different interventions. The measured endpoint matters too: a safety study is not automatically a demonstration of weight-loss effectiveness.^[2][3]

Descriptions such as fat breakdown or metabolic support can summarize a research question. They should not turn a proposed mechanism into a promised result for the person reading a dosage chart.

U-100 units are volume markings, not peptide international units. One unit is 0.01 mL. A concentration belongs to a particular final volume, so the same syringe marking will contain a different mass after a different dilution.

Check the syringe’s capacity and graduations separately from the device used to measure the full preparation volume. A vial’s nominal capacity does not independently verify solubility, sterile preparation, or compatibility with bacteriostatic water.

CDC’s general injection-safety guidance calls for new sterile equipment when accessing a vial and disposal of used needles and syringes. It does not approve an AOD-9604 formulation or protocol.^[16]

This dosage chart provides educational calculations and research context. It does not establish the safety or effectiveness of AOD-9604 for human use or replace medical assessment.

• 1
  
  Journal of Endocrinology and Metabolism (2014)
  : Safety and metabolism of AOD9604 as a nutraceutical ingredient; mechanism of action and metabolic studies

  View Source
• 2
  
  Journal of Endocrinology and Metabolism (2013)
  : Safety and tolerability of AOD9604 in humans; no IGF‑1 increase; placebo‑like safety profile

  View Source
• 3
  
  FDA Pharmacy Compounding Advisory Committee (2024)
  : AOD‑9604 bulk drug substance meeting memorandum; regulatory and safety overview

  View Source
• 4
  
  Endocrinology (OUP)
  : Effects of hGH and AOD9604 on lipid metabolism in obese mice; β‑adrenergic pathway mechanisms

  View Source
• 15
  FDA: AOD-9604 compounding safety concerns and evidence limitations

  View Source
• 16
  CDC: Safe injection practices and vial-access equipment

  View Source
• 17
  MilliporeSigma: Handling Storage, general laboratory guidance for lyophilized peptides and peptide solutions; not an AOD-9604 product stability study

  View Source
• 18
  Thermo Fisher Scientific: Standard Peptide Custom Synthesis Service, general storage and handling guidance; solution stability depends on the peptide

  View Source
• 19
  FDA: Lyophilization of Parenteral (7/93), product-specific reconstitution stability and sterility-testing considerations

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.